Department of Orthopedics, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
The Key Laboratory of Digital Orthopedics of Yunnan Province, Kunming, Yunnan, China.
Cancer Med. 2024 Aug;13(15):e70058. doi: 10.1002/cam4.70058.
Chondrosarcoma (CHS), a bone malignancy, poses a significant challenge due to its heterogeneous nature and resistance to conventional treatments. There is a clear need for advanced prognostic instruments that can integrate multiple prognostic factors to deliver personalized survival predictions for individual patients. This study aimed to develop a novel prediction tool based on recursive partitioning analysis (RPA) to improve the estimation of overall survival for patients with CHS.
Data from the Surveillance, Epidemiology, and End Results (SEER) database were analyzed, including demographic, clinical, and treatment details of patients diagnosed between 2000 and 2018. Using C5.0 algorithm, decision trees were created to predict survival probabilities at 12, 24, 60, and 120 months. The performance of the models was assessed through confusion scatter plot, accuracy rate, receiver operator characteristic (ROC) curve, and area under ROC curve (AUC).
The study identified tumor histology, surgery, age, visceral (brain/liver/lung) metastasis, chemotherapy, tumor grade, and sex as critical predictors. Decision trees revealed distinct patterns for survival prediction at each time point. The models showed high accuracy (82.40%-89.09% in training group, and 82.16%-88.74% in test group) and discriminatory power (AUC: 0.806-0.894 in training group, and 0.808-0.882 in test group) in both training and testing datasets. An interactive web-based shiny APP (URL: https://yangxg1209.shinyapps.io/chondrosarcoma_survival_prediction/) was developed, simplifying the survival prediction process for clinicians.
This study successfully employed RPA to develop a user-friendly tool for personalized survival predictions in CHS. The decision tree models demonstrated robust predictive capabilities, with the interactive application facilitating clinical decision-making. Future prospective studies are recommended to validate these findings and further refine the predictive model.
软骨肉瘤(CHS)是一种骨恶性肿瘤,由于其异质性和对传统治疗的耐药性,带来了重大挑战。显然需要先进的预后工具,将多个预后因素整合起来,为个体患者提供个性化的生存预测。本研究旨在开发一种基于递归分区分析(RPA)的新预测工具,以提高对 CHS 患者总体生存的估计。
分析了来自监测、流行病学和最终结果(SEER)数据库的数据,包括 2000 年至 2018 年期间诊断的患者的人口统计学、临床和治疗细节。使用 C5.0 算法,创建决策树以预测 12、24、60 和 120 个月的生存概率。通过混淆散点图、准确率、接收者操作特征(ROC)曲线和 ROC 曲线下面积(AUC)评估模型的性能。
研究确定了肿瘤组织学、手术、年龄、内脏(脑/肝/肺)转移、化疗、肿瘤分级和性别是关键预测因素。决策树揭示了每个时间点生存预测的不同模式。模型在训练组中的准确率为 82.40%-89.09%,在测试组中的准确率为 82.16%-88.74%,具有较高的准确性和区分能力(AUC:训练组为 0.806-0.894,测试组为 0.808-0.882)。开发了一个交互式网络 shiny APP(网址:https://yangxg1209.shinyapps.io/chondrosarcoma_survival_prediction/),简化了临床医生的生存预测过程。
本研究成功地运用 RPA 为 CHS 患者开发了一个用户友好的个性化生存预测工具。决策树模型表现出强大的预测能力,交互式应用程序有助于临床决策。建议进行未来的前瞻性研究来验证这些发现,并进一步改进预测模型。